----

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549**

**FORM      10-QSB**

**A      J&J PHARMA CORPORATION**

----

|  NEVADA                                                                        |  86-1024812                                    |
|-------------------------------------------------------------------------------------|-----------------------------------------------------|
|  (State                or other jurisdiction of incorporation or organization) | (I.R.S.                Employer Identification No.) |

----

----

----

**A      J&J PHARMA CORPORATION**

**(A      DEVELOPMENT STAGE COMPANY)**

|   **TABLE                OF CONTENTS** |
|--------------------------------------------------|
|                                             |   |   |   |   |   |   |   |   |
|                                             |   |   |   |   |   |   |   | Page |
| Part                I                            | Financial                Information | 3 |
|                                             |   |   |   |   |   |   |   |   |
| Item                1.                           | Financial                Statements: | 3 |
|                                             |   |   |   |   |   |   |   |   |
|                                             | Condensed                Balance Sheets March 31, 2007 (unaudited) and December 31,                2006 |  3 |
|                                             |   |   |
|                                             | Unaudited                Condensed Statements of Operations for the three months ended March                31,                2007 and 2006, and cumulative from inception on July 16, 1998 through                March 31, 2007 |  4 |
|                                             |   |   |
|                                             | Unaudited                Condensed Statements of Cash Flows for the three months ended March                31,                2007 and 2006, and cumulative from inception on July 16, 1998 through                March 31, 2007 |  5 |
|                                             |   |   |
|                                             | Statement                of Stockholders' Deficit for the period from July 16,1998 to March                31,                2007 (unaudited) |  6 |
|                                             |   |   |
|                                             |  Notes                to Financial Statements (unaudited) |  7 |
|                                             |   |   |
| Item                2.                           |  Plan                of Operation |  7 |
|                                             |   |   |
|  Part                II                     |  Other                Information |  7 |
|                                             |   |   |
|  Item                1.                     |  Legal                Proceedings |  7 |
|                                             |   |   |
|  Item                2.                     |  Changes                in Securities |  7 |
|                                             |   |   |
|  Item                6.                     |  Exhibits                and Reports on Form 8-K |  7 |
|                                             |   |   |
|                                             |  Signatures |  8 |

----

| **A.J.                & J. PHARMA, INC.**                                         |
|--------------------------------------------------------------------------------------------|
| **(A                DEVELOPMENT STAGE ENTERPRISE)**                                   |
| **CONDENSED                BALANCE SHEETS**                                           |
|                                                                                       |   |
|                                                                                       |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |
|                                                                                       |   | **March                31,** |   |   | **December                31,** |   |
|                                                                                       |   | **2007** |   |   | **2006** |   |
|                                                                                       |   | **(unaudited)** |   |   |   |   |
| **ASSETS**                                                   |
|                                                                                       |   |   |   |   |   |   |
|  **CURRENT                ASSETS**                                                    |   | $ | - |   |   | $ | - |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
| **LIABILITIES                AND STOCKHOLDERS' DEFICIT**                                   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
| **CURRENT                LIABILITIES**                                                     |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|        Accounts                payable, related parties |   | $ | 41,593 |   |   | $ | 39,864 |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|        Total                Current Liabilities         |   |   | 41,593 |   |   |   | 39,864 |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
| **STOCKHOLDERS'                DEFICIT**                                                   |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
| Common                stock, par value $.001, 25,000,000                                   |   |   |   |   |   |   |   |   |
|   shares                authorized, 1,000,000 issued and                         |   |   |   |   |   |   |   |   |
|   outstanding                                                                    |   |   | 1,000 |   |   |   | 1,000 |   |
| Paid                in capital                                                             |   |   | 1,800 |   |   |   | 1,800 |   |
|  Accumulated                deficit during the development stage                      |   |   | (44,393 | ) |   |   | (42,664 | ) |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
| Total                Stockholders' accumulated Deficit                                     |   |   | (41,593 | ) |   |   | (39,864 | ) |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   | $ | - |   |   | $ | - |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
|                                                                                       |   |   |   |   |   |   |   |   |
| SEE                ACCOMPANYING NOTES TO FINANCIAL                STATEMENTS               |

----

| **A.J.                & J. PHARMA, INC.**                           |
|------------------------------------------------------------------------------|
| **(A                DEVELOPMENT STAGE ENTERPRISE)**                     |
| **CONDENSED                STATEMENTS OF OPERATIONS**                   |
| **(UNAUDITED)**                                                              |   |
|                                                                         |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   | **Cumulative** |   |
|                                                                         |   |   |   |   |   |   |   | **from** |   |
|                                                                         |   |   |   |   |   |   |   | **July                16,** |   |
|                                                                         |   |   |   |   |   |   |   | **1998** |   |
|                                                                         |   | **For                The Three Months Ended** |   |   | **(Inception)** |   |
|                                                                         |   | **March                31,** |   |   | **to** |   |
|                                                                         |   | **2007** |   |   | **2006** |   |   | **March                31, 2007** |   |
|                                                                         |   |   |   |   |   |   |   |   |   |
| **REVENUES**                                                                 |   | $ | - |   |   | $ | - |   |   | $ | - |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
| **EXPENSES**                                                                 |   |   |   |   |   |   |   |   |   |   |   |   |
|    General                and administrative                  |   |   | 1,729 |   |   |   | 2,688 |   |   |   | 44,393 |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|    Total                expenses                              |   |   | 1,729 |   |   |   | 2,688 |   |   |   | 44,393 |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
| **NET                (LOSS)**                                                |   | $ | (1,729 | ) |   | $ | (2,688 | ) |   | $ | (44,393 | ) |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
| **NET                (LOSS) PER SHARE**                                      |   |   | * |   |   |   | * |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
| **WEIGHTED                AVERAGE NUMBER OF**                                |   |   |   |   |   |   |   |   |   |   |   |   |
|   **COMMON                SHARES OUTSTANDING**                     |   |   | 1,000,000 |   |   |   | 1,000,000 |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
| *                less than $ (0.01) per share                                |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                         |   |   |   |   |   |   |   |   |   |   |   |   |
| SEE                ACCOMPANYING NOTES TO FINANCIAL                STATEMENTS |

----

| **A.J.                & J. PHARMA, INC.**                                                      |
|---------------------------------------------------------------------------------------------------------|
| **(A                DEVELOPMENT STAGE ENTERPRISE)**                                                |
| **CONDENSED                STATEMENTS OF CASH FLOWS**                                              |
| **(UNAUDITED)**                                                                                    |
|                                                                                                    |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   | **Cumulative** |   |
|                                                                                                    |   |   |   |   |   |   |   | **from** |   |
|                                                                                                    |   |   |   |   |   |   |   | **July                16,** |   |
|                                                                                                    |   |   |   |   |   |   |   | **1998** |   |
|                                                                                                    |   | **For                The Three Months Ended** |   |   | **(Inception)** |   |
|                                                                                                    |   | **March                31,** |   |   | **to** |   |
|                                                                                                    |   | **2007** |   |   | **2006** |   |   | **March                31, 2007** |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |
| **OPERATING                ACTIVITIES**                                                                 |   |   |   |   |   |   |   |   |   |
|          Net                (loss) from operations         |   | $ | (1,729 | ) |   | $ | (2,688 | ) |   | $ | (44,393 | ) |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
| **NET                CASH (USED BY) OPERATING ACTIVITIES**                                              |   |   | (1,729 | ) |   |   | (2,688 | ) |   |   | (44,393 | ) |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
| **FINANCING                ACTIVITIES**                                                                 |   |   |   |   |   |   |   |   |   |   |   |   |
|          Accounts                payable, related parties  |   |   | 1,729 |   |   |   | 2,688 |   |   |   | 41,593 |   |
|          Proceeds                from sale of common stock |   |   | - |   |   |   | - |   |   |   | 2,800 |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
| **NET                CASH PROVIDED BY FINANCING ACTIVITIES**                                            |   |   | 1,729 |   |   |   | 2,688 |   |   |   | 44,393 |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
| **NET                INCREASE IN CASH**                                                                 |   |   | (0 | ) |   |   | (0 | ) |   |   | - |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
| **CASH,                BEGINNING OF PERIOD**                                                            |   |   | - |   |   |   | - |   |   |   | - |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
| **CASH,                END OF PERIOD**                                                                  |   | $ | (0 | ) |   | $ | (0 | ) |   | $ | - |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
| SEE                ACCOMPANYING NOTES TO FINANCIAL                STATEMENTS                            |

----

| **A.J.                  & J. PHARMA, INC.**         |   |
|---------------------------------------------------------|--------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**   |   |
| **STATEMENT                  OF STOCKHOLDERS' DEFICIT** |   |
|                                                    |   |   |

|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |
|----------------------------------------------------------------------------------------|--------|-----------------------------------|-----------|--------|-------------|--------|--------|-----------------|--------|--------|------------------------------------------|--------|--------|-----------|---------|
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   | **Accumulated                  Deficit** |   |   |      |    |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   | **During                  the**          |   |   |      |    |
|                                                                                   |   | **Common                  Stock** |      |   | **Paid-in** |   |   | **Development** |   |   |                                     |   |
|                                                                                   |   | **Shares**                        |      |   | **Amount**  |   |   | **Capital**     |   |   | **Stage**                                |   |   | **Total** |    |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |
| **Balances,                  at inception**                                            |   |                              | -         |   |        | $      | -      |            |   | $      | -                                        |   |   | $         | -       |   |   | $ | - |   |
| July                  16, 1998:                                                        |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| Proceeds                  from sale of common                                          |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|   stock                  at $.01 per share                                   |   |                              | 200,000   |   |        |   | 200    |            |   |   | 1,800                                    |   |   |      |    |   |   |   | 2,000 |   |
| Proceeds                  from sale of common                                          |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|   stock                  at par value $.001                                  |   |                              | 800,000   |   |        |   | 800    |            |   |   |                                     |   |   |      |    |   |   |   | 800 |   |
|   Net                  (loss) for the period                                 |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      | (2,385  | ) |   |   | (2,385 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| **Balances,                  December 31, 1998**                                       |   |                              | 1,000,000 |   |        |   | 1,000  |            |   |   | 1,800                                    |   |   |      | (2,385  | ) |   |   | 415 |   |
|   Net                  (loss) for the year                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      | (2,985  | ) |   |   | (2,985 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| **Balances,                  December 31, 1999**                                       |   |                              | 1,000,000 |   |        |   | 1,000  |            |   |   | 1,800                                    |   |   |      | (5,370  | ) |   |   | (2,570 | ) |
|   Net                  (loss) for the year                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      | (2,985  | ) |   |   | (2,985 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| **Balances,                  December 31, 2000**                                       |   |                              | 1,000,000 |   |        |   | 1,000  |            |   |   | 1,800                                    |   |   |      | (8,355  | ) |   |   | (5,555 | ) |
|   Net                  (loss) for the year                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      | (5,685  | ) |   |   | (5,685 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| **Balances,                  December 31, 2001**                                       |   |                              | 1,000,000 |   |        |   | 1,000  |            |   |   | 1,800                                    |   |   |      | (14,040 | ) |   |   | (11,240 | ) |
|   Net                  (loss) for the year                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      | (4,335  | ) |   |   | (4,335 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| **Balances,                  December 31, 2002**                                       |   |                              | 1,000,000 |   |        |   | 1,000  |            |   |   | 1,800                                    |   |   |      | (18,375 | ) |   |   | (15,575 | ) |
|   Net                  (loss) for the year                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      | (4,358  | ) |   |   | (4,358 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| **Balances,                  December 31, 2003**                                       |   |                              | 1,000,000 |   |        |   | 1,000  |            |   |   | 1,800                                    |   |   |      | (22,733 | ) |   |   | (19,933 | ) |
|   Net                  (loss) for the year                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      | (6,605  | ) |   |   | (6,605 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| **Balances,                  December 31, 2004**                                       |   |                              | 1,000,000 |   |        |   | 1,000  |            |   |   | 1,800                                    |   |   |      | (29,338 | ) |   |   | (26,538 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|   Net                  (loss) for the year                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      | (6,590  | ) |   |   | (6,590 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| **Balances,                  December 31, 2005**                                       |   |                              | 1,000,000 |   |        |   | 1,000  |            |   |   | 1,800                                    |   |   |      | (35,928 | ) |   |   | (33,128 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|   Net                  (loss) for the year                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      | (6,736  | ) |   |   | (6,736 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| **Balances,                  December 31, 2006**                                       |   |                              | 1,000,000 |   |        |   | 1,000  |            |   |   | 1,800                                    |   |   |      | (42,664 | ) |   |   | (39,864 | ) |
| **(unaudited)**                                                                        |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|   Net                  (loss) for the three months                           |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      | (1,729  | ) |   |   | (1,729 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
| **Balances,                  March 31, 2007 (unaudited)**                              |   |                              | 1,000,000 |   |        | $      | 1,000  |            |   | $      | 1,800                                    |   |   | $         | (44,393 | ) |   | $ | (41,593 | ) |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|                                                                                   |   |                              |      |   |        |   |   |            |   |   |                                     |   |   |      |    |   |   |   |   |   |
|  SEE                  ACCOMPANYING NOTES TO FINANCIAL                  STATEMENTS |

----

**A        J&J PHARMA CORPORATION**

**(A        DEVELOPMENT STAGE COMPANY)**

**NOTES        TO FINANCIAL STATEMENTS        (UNAUDITED)**

**Note      1. Basis of Presentation**

**Note      2. Going Concern**

| 31.1 | Certificate                of CEO as Required by Rule                13a-14(a)/15d-14                                                                                                                                                                     |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31.2 | Certificate                of CFO as Required by Rule                13a-14(a)/15d-14                                                                                                                                                                     |
| 32.1 | Certificate                of CEO & CFO as Required by Rule                Rule 13a-14(b) and Rule 15d-14(b) (17 CFR 240.15d-14(b)) and Section                1350                of Chapter 63 of Title 18 of the United States                Code |

----

----